explore -WSS

explore

author：focus 2025-09-27 22:06:22 - browse：211

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Using force crossed my mind when examining a defiant young patient

WSS

Will General Catalyst be the first of many hospital takeovers?

5 ways to address the shortage of health care workers

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

UCSF medical school apologizes for unethical prisoner experiments

Victims of gun violence feel impacts long after bullet wound

Change Healthcare cyberattack shows risk of industry consolidation

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FDA approves potent Eli Lilly obesity drug, Zepbound

Malaria cases in Florida and Texas: Here’s what you need to know

Change Healthcare cyberattack shows risk of industry consolidation

Tori Bowie and the unacceptable rates of Black maternal death

Neuroscience renaissance leads to new crop of psychiatric drugs

Supreme Court strikes down use of affirmative action

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

23andMe had bad news about my health. I wish a person had delivered it

Medicare Advantage isn’t working — for anyone

knowledge

Are embryos people? Reproductive medicine's future depends on the answer

Neuroscience renaissance leads to new crop of psychiatric drugs

Senate panel clears PBM, hopsital reforms

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Using force crossed my mind when examining a defiant young patient

Color Health wants to make cancer screenings convenient

knowledge

focus

leisure time

explore